about
Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from SwedenPercentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions--a meta-analysisThe impact of duration of treatment on reported time-to-onset in spontaneous reporting systems for pharmacovigilancePrevalence and perceived preventability of self-reported adverse drug events--a population-based survey of 7099 adultsEconomic impact of adverse drug events--a retrospective population-based cohort study of 4970 adultsImpact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study.N-acetylcysteine amide decreases oxidative stress but not cell death induced by doxorubicin in H9c2 cardiomyocytes.Medication errors related to transdermal opioid patches: lessons from a regional incident reporting systemPrevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults.Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers.Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?On the pedagogy of pharmacological communication: a study of final semester health science studentsPotentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study.Incidence of fatal adverse drug reactions: a population based study.Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.Rhabdomyolysis a result of azithromycin and statins: an unrecognized interactionRefill adherence and self-reported adverse drug reactions and sub-therapeutic effects: a population-based study.The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.Excretion of fluvoxamine into breast milk.[Drug-induced liver injury from the dietary supplement Fortodol. A manipulated preparation delayed the diagnosis].[The effect of warfarin was potentiated by an antitussive. Cocillana-Etyfin increased the PK(INR) value].Tramadol dependence: a survey of spontaneously reported cases in Sweden.Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics.The major fluvoxamine metabolite in urine is formed by CYP2D6.Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis.Glucose intolerance with atypical antipsychotics.Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis.Clozapine and pulmonary embolism.Effects of cocoa extract and dark chocolate on angiotensin-converting enzyme and nitric oxide in human endothelial cells and healthy volunteers--a nutrigenomics perspective.Fatal unintentional intoxications with tramadol during 1995-2005.Olanzapine and venous thromboembolism.Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions.Preventable drug related mortality in a Swedish population.[New antidepressive agents during pregnancy and lactation. Drug concentration should be monitored and the lowest possible dose administered].Therapeutic drug monitoring of ziprasidone in a clinical treatment setting.A prospective analysis of the preventability of adverse drug reactions reported in Sweden.Modelling drug-related morbidity in Sweden using an expert panel of physicians.Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden.
P50
Q28218663-B94265E6-C4B8-4936-BB87-7B5D7AA0B08EQ28481506-FD865159-3B54-4731-86AC-AE66592E0983Q28534667-6E2B3CAC-D538-4F66-87BB-EA27AE0020EFQ28536709-B4291D0B-8694-4D6D-995B-FA6EA7A39300Q28540999-7B13F157-50A3-45F6-9A15-6665B5EFC385Q31030474-EA60E93B-12BC-4E29-934E-0ECC832ED6D7Q33430517-C7B22FE5-27BA-413E-9BA8-C3BA329EB2BCQ33773016-6F07D096-1F7A-4AC7-9B93-FBADCB5EBFD4Q34209590-1F27B197-59C1-40F9-B82A-BE91B5E8587FQ35026492-8C98EFAD-A2E8-4B84-A774-A15C9DCC1018Q35770395-1BF3F80F-4293-44E9-8651-56233B666BB5Q35821729-F890930B-6203-49AD-B87F-12B90A00CEA6Q36275087-58CB8260-A691-487F-8A1A-6394F97FB216Q36536453-0F8E3927-003E-4C4B-BF59-B68A955E5575Q37152047-F89ED4B4-B15E-4724-B1DB-C77DABDD2C4FQ37397811-5025DE5F-6C7F-4C16-81BF-B61748160114Q38152746-CDC2A722-1924-4D47-9C92-1D11920063B2Q41111639-843AF336-C851-4AE8-9721-FAF90E8D1DE9Q42561479-B980AC12-5D52-4008-9B22-21614E2D38B9Q43120185-2ABDFA7C-74E4-4184-A0CC-A18509637F73Q43226615-F6011CBB-5692-416E-B0A7-627CFBEAFFF5Q43261893-A685FC11-0426-438A-9392-5A5D3963EBDEQ43528853-CE2F6D18-126F-4B89-9841-12726926C29EQ43792965-FF571C9F-7B08-46CA-A57A-DCCACF139EE4Q43844459-57BECED4-FB3C-44E7-AF7E-043F81851257Q43855003-3D2BDB38-B30B-4E13-8AEB-83EA0351214DQ44018630-49DA51B0-1C19-408F-AC60-F028A071391EQ44229906-C4E9D537-AE89-4A51-9F81-DC2EF6564247Q44408630-336CEFF8-1EFE-430B-A41A-F0E5E089B102Q44478461-D7CE9A22-769E-4258-833C-40143B1775C4Q44540113-1CEA554B-295D-461C-9A84-1646B96E8D8CQ44547890-AA3C8059-102E-4DDF-AC2C-47279459AFD3Q44550760-CA7C21CA-F1B3-4E1C-B4E6-1E0D7322E3BBQ44594548-CCF6D660-0E12-403D-B444-50A166CD4295Q44672393-8F6CE9F8-3940-4D88-A84D-11D995D8F8C9Q44854047-6F14026A-BC27-42D8-9A32-42F95CA076F5Q44955519-81488E4F-BEDC-436D-9A79-4439F8B75A99Q45284924-BC9F291A-102E-4C4C-852A-1ABC05FE65A7Q45420124-C08C4EAA-471F-43F8-845C-EC53AA746867Q45907488-47ECC2C3-EE8A-4ED4-AC53-DA6195CF7ACA
P50
description
Zweeds onderzoeker
@nl
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Staffan Hägg
@ast
Staffan Hägg
@en
Staffan Hägg
@es
Staffan Hägg
@nl
Staffan Hägg
@sl
type
label
Staffan Hägg
@ast
Staffan Hägg
@en
Staffan Hägg
@es
Staffan Hägg
@nl
Staffan Hägg
@sl
prefLabel
Staffan Hägg
@ast
Staffan Hägg
@en
Staffan Hägg
@es
Staffan Hägg
@nl
Staffan Hägg
@sl
P1053
G-5612-2013
P106
P1153
7003351466
P21
P27
P31
P3829
P496
0000-0002-5137-8420